Careteq (ASX: CTQ) Maintains ASX Listing Post-EHS Divestment, Focuses on Expanding HMR Referrals Marketplace

ASX Confirms Ongoing Quotation Following Strategic Divestment

Careteq Limited received formal confirmation from the Australian Securities Exchange that its securities will continue to be listed following the divestment of its Embedded Health Solutions (EHS) subsidiary. This confirmation resolves prior regulatory uncertainties linked to the divestment and affirms that Careteq maintains sufficient operational scale and financial health to warrant ongoing quotation. The ASX’s decision followed detailed consultations regarding Careteq’s operational plans, strategic objectives, and intended use of funds from the EHS sale.

This regulatory clearance removes a significant hurdle, allowing Careteq to confidently pursue its refocused business strategy. The ASX’s endorsement indicates satisfaction with the company’s strategic direction and the viability of the HMR Referrals marketplace as a standalone business capable of meeting listing requirements.

HMR Referrals Marketplace Becomes Careteq’s Core Business Post-Divestment

With the completion of the EHS divestment, Careteq’s sole operating business is now the HMR Referrals platform. This Software-as-a-Service two-sided marketplace connects general practitioners with credentialed pharmacists to facilitate Home Medicines Reviews (HMRs), a government-subsidized service reimbursed under Medicare Benefits Schedule (MBS) Item 900. This specialization situates Careteq within a defined regulatory and reimbursement framework, providing revenue stability linked to government health policies.

The HMR Referrals network has scaled significantly, comprising over 500 accredited pharmacists, approximately 80 GP clinics, and 400 general practitioners across Australia. This extensive network creates a competitive moat, as the platform’s value grows with increased participants on both sides, demonstrating strong provider adoption and market presence.

March Quarter Results Highlight Positive Cash Flow and Revenue Growth

Careteq reported customer receipts of $2.192 million for the March quarter, up from $2.098 million in the December quarter, indicating sustained revenue growth amid operational transitions including the EHS divestment and capital raising. The company achieved positive net operating cash flow of $14,000 during the quarter, a notable improvement from a $95,000 outflow in the prior period. This positive cash flow signals improved operational efficiency and balance between revenue and expenses.

Further updates on the June quarter performance will be provided in the upcoming Q4-FY26 Activities Report and Appendix 4C cash flow statement, offering investors greater insight into the company’s post-restructuring progress.

Strategic Priorities for the Next 12 Months: Network Expansion and Clinic Activation

Careteq has identified three primary strategic priorities to strengthen its market position over the coming year. First, the company aims to deepen engagement within its accredited pharmacist and GP clinic networks, focusing on targeted geographic expansion and integrating its platform with leading practice management systems to enhance workflow integration and provider adoption.

Second, Careteq plans to implement a standardized clinic activation program designed to convert underutilized capacity within existing GP clinics into increased referral volumes, addressing latent demand without necessarily expanding the clinic network.

Third, the company intends to explore adjacent healthcare programs, including potential extensions of the HMR Referrals marketplace into complementary community pharmacy services leveraging its existing network infrastructure.

Advancing Artificial Intelligence Strategy and Strategic Opportunity Assessment

Careteq has indicated intentions to develop an artificial intelligence (AI) strategy as part of its long-term growth plan. While specific AI initiatives and timelines remain undisclosed, the company is actively monitoring healthcare technology trends and considering capability partnerships, technology collaborations, and strategic acquisitions aligned with both growth and AI objectives.

The Board emphasizes a disciplined evaluation framework, prioritizing shareholder value creation and remaining selective regarding acquisitions and partnerships. This approach reflects the company’s view of AI as a potential differentiator within the healthcare services technology sector.

Capital Raising Completed; Funds Allocated to Strategic Growth Initiatives

During the March quarter, Careteq completed a two-tranche capital raising, supplementing proceeds from the EHS divestment to fund operational activities. The company disclosed a proposed use of funds supporting its strategic priorities, including clinic activation, pharmacist recruitment, and sector engagement. Capital deployment will be staged to allow management to evaluate returns and adjust resource allocation accordingly.

The Board considers current funding sufficient to support planned activities over the next 12 months without requiring additional capital. Careteq commits to transparent reporting on capital deployment and progress against strategic objectives in its quarterly activity reports.

Operating Within Australia’s Medicare Benefits Schedule Framework

Careteq operates within the Australian government-subsidized healthcare services market, specifically under Medicare Benefits Schedule Item 900, which reimburses Home Medicines Reviews. This framework offers revenue predictability tied to government funding decisions but also limits market size to eligible patient volumes and government allocations.

The company’s focus on converting underutilized HMR capacity suggests significant referral growth potential within existing reimbursement parameters, without reliance on policy changes. Exploration of adjacent community pharmacy programs may further expand the addressable market leveraging existing provider networks.

Competitive Advantages and Network Effects in Home Medicines Review Market

The HMR Referrals platform benefits from strong network effects, connecting over 500 accredited pharmacists and 400 GPs across approximately 80 clinics nationwide. This scale creates switching costs and mutual dependencies that protect the platform from competitors by enhancing utility for both pharmacists and GPs.

Careteq’s emphasis on deepening network engagement in targeted regions and integrating with practice management systems aims to strengthen these competitive advantages by embedding the platform within healthcare workflows and increasing provider retention.

Financial Sustainability and Progress Toward Profitability

The shift to positive operating cash flow in the March quarter marks a key milestone, indicating that the HMR Referrals business is moving toward self-sufficiency. Generating $14,000 in net operating cash flow on $2.192 million in receipts demonstrates improving unit economics during a period of significant operational change.

The Board’s confidence in funding sufficiency for 12 months depends on successful execution of growth initiatives to expand referrals and manage expenses. The staged capital deployment approach provides flexibility to optimize expenditure based on performance outcomes.

Risks and Execution Challenges

Careteq’s strategic success depends on effectively executing network expansion, clinic activation, and evaluation of complementary opportunities. Execution risks include potential underperformance in referral growth, higher-than-expected recruitment costs, and integration challenges from acquisitions or partnerships.

Additionally, the company faces regulatory risk tied to government decisions on Medicare Benefits Schedule inclusion and reimbursement rates for HMR services, which could materially impact revenue regardless of operational execution. The company has not disclosed the proportion of revenue derived from MBS-funded HMR services versus other sources.